Genitourinary Cancers Symposium

Bone loss was observed in both treatment arms, but abiraterone plus prednisone did not increase bone loss.

By blinded independent review, there was a 39% reduction in the risk of progression or death with olaparib.

Compared with German and US patients, UK patients were less likely to be diagnosed with prostate cancer via routine screening.

Men of African ancestry had the highest risk of developing metastatic prostate cancer when compared with men of other ancestries.